A Phase 1 trial of ARX788 in HER2-positive advanced gastric patients who have been previously treated
Latest Information Update: 07 Oct 2021
At a glance
- Drugs ARX 788 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms ACE-Gastric-01
- Sponsors Ambrx
- 04 Oct 2021 According to an Ambrx media release, trial has completed the enrollment of 30 patients.
- 04 Oct 2021 Positive interim data from this trial were presented at The Chinese Society of Clinical Oncology (CSCO).
- 04 Oct 2021 Positive interim data (data as of June 30, 2021) published in an Ambrx Media Release.